Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J D Bitran

Showing results (41-50 of 119) with videos related to

Pageof 12
Sort By:
JAMA|December 15, 1978
Metastatic non-oat-cell bronchogenic carcinoma. Therapy with cyclophosphamide, doxorubicin, methotrexate, and procarbazine (CAMP)J D Bitran, R K Desser, T DeMeester, et al.
JAMA|March 16, 1979
Gallium 67 scans in small cell carcinomaJ D Bitran, C Bekerman, S Pinsky, et al.
CA: a Cancer Journal for Clinicians|September 1, 1984
Current concepts in small cell carcinoma of the lungP C Hoffman, K S Albain, J D Bitran, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 1, 1995
A phase I study of ifosfamide and doxorubicin with recombinant human granulocyte colony-stimulating factor in stage IV breast cancerJ D Bitran, B L Samuels, S Marsik, et al.
American Journal of Clinical Oncology|February 1, 1995
A phase II study of recombinant interferon-gamma following combination chemotherapy for patients with extensive small cell lung cancer. CALGBJ D Bitran, M Green, M Perry, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 1, 1996
Her2/neu overexpression is associated with treatment failure in women with high-risk stage II and stage IIIA breast cancer (>10 involved lymph nodes) treated with high-dose chemotherapy and autologous hematopoietic progenitor cell support following standard-dose adjuvant chemotherapyJ D Bitran, B Samuels, Y Trujillo, et al.
Breast Cancer Research and Treatment|December 1, 1993
Mitoxantrone, vincristine, and 5-fluorouracil with leucovorin modulation as induction chemotherapy prior to high-dose intensification in metastatic breast cancerS F Williams, S E Myers, S Huffman, et al.
The American Journal of Medicine|December 1, 1990
Role of systemic therapy in advanced non-small-cell lung cancerE E Vokes, S Vijayakumar, J D Bitran, et al.
Journal of the National Cancer Institute|January 3, 1990
High-dose tri-alkylator chemotherapy with autologous stem cell rescue in patients with refractory malignanciesJ A Moormeier, S F Williams, L S Kaminer, et al.
Journal of Chemotherapy (Florence, Italy)|July 23, 2009
Docetaxel and oxaliplatin as first-line therapy for advanced non-small cell lung cancer: a phase II trialA Radhakrishnan, J D Bitran, D T Milton, et al.
Pageof 12

Showing results (41-50 of 119) with videos related to

Sort By:
Pageof 12
JAMA|December 15, 1978
Metastatic non-oat-cell bronchogenic carcinoma. Therapy with cyclophosphamide, doxorubicin, methotrexate, and procarbazine (CAMP)J D Bitran, R K Desser, T DeMeester, et al.
JAMA|March 16, 1979
Gallium 67 scans in small cell carcinomaJ D Bitran, C Bekerman, S Pinsky, et al.
CA: a Cancer Journal for Clinicians|September 1, 1984
Current concepts in small cell carcinoma of the lungP C Hoffman, K S Albain, J D Bitran, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 1, 1995
A phase I study of ifosfamide and doxorubicin with recombinant human granulocyte colony-stimulating factor in stage IV breast cancerJ D Bitran, B L Samuels, S Marsik, et al.
American Journal of Clinical Oncology|February 1, 1995
A phase II study of recombinant interferon-gamma following combination chemotherapy for patients with extensive small cell lung cancer. CALGBJ D Bitran, M Green, M Perry, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 1, 1996
Her2/neu overexpression is associated with treatment failure in women with high-risk stage II and stage IIIA breast cancer (>10 involved lymph nodes) treated with high-dose chemotherapy and autologous hematopoietic progenitor cell support following standard-dose adjuvant chemotherapyJ D Bitran, B Samuels, Y Trujillo, et al.
Breast Cancer Research and Treatment|December 1, 1993
Mitoxantrone, vincristine, and 5-fluorouracil with leucovorin modulation as induction chemotherapy prior to high-dose intensification in metastatic breast cancerS F Williams, S E Myers, S Huffman, et al.
The American Journal of Medicine|December 1, 1990
Role of systemic therapy in advanced non-small-cell lung cancerE E Vokes, S Vijayakumar, J D Bitran, et al.
Journal of the National Cancer Institute|January 3, 1990
High-dose tri-alkylator chemotherapy with autologous stem cell rescue in patients with refractory malignanciesJ A Moormeier, S F Williams, L S Kaminer, et al.
Journal of Chemotherapy (Florence, Italy)|July 23, 2009
Docetaxel and oxaliplatin as first-line therapy for advanced non-small cell lung cancer: a phase II trialA Radhakrishnan, J D Bitran, D T Milton, et al.
Pageof 12